Journal: Scientific Reports

Article Title: Clinical performance of an analytically validated assay in comparison to microarray technology to assess PITX2 DNA-methylation in breast cancer

doi: 10.1038/s41598-018-34919-1

Figure Lengend Snippet: Determination of PITX2 cut-off points and Kaplan Meier analysis. ( a) Statistical analysis of PITX2 cut-off points (PMR) for all patients (n = 204). Microarray gLOG data were converted with 2exp(gLOG) function to calculated PITX2 PMR data (PMR calc ); x-axis: Calculated PITX2 PMR data [%]; y-axis: Standardized log-rank statistics. Dashed vertical line marks the maximum cut-off point of PITX2 PMR calc at 14.73. ( b) Kaplan-Meier analysis for DFS of high-risk breast cancer patients (n = 204) using the maximum PITX2 cut-off point (PMR calc = 14.73). Patients were treated with anthracycline-based chemotherapy ± endocrine therapy (HR 2.321; p < 0.001). Upper line: patients with PMR ≤ 14.73. Lower line: patients with PMR > 14.73. ( c) Kaplan-Meier analysis for DFS of subgroup of high-risk breast cancer patients treated with anthracycline-based chemotherapy and additional endocrine therapy (n = 96) using the maximum PITX2 cut-off point (PMR calc = 14.73) (HR 2.285; p = 0.024). Upper line: patients with PMR ≤ 14.73. Lower line: patients with PMR > 14.73. ( d) Statistical evaluation of PITX2 DNA percent methylation ratio (PMR) cut-off points. PMR data (n = 204) are equivalent (PMR equiv ) to therascreen PITX2 RGQ PCR assay determined PMR values. x-axis: equivalent PITX2 PMR [%]; y-axis: Standardized log-rank statistics. The dashed vertical line marks the maximum log-rank statistic at a PITX2 PMR cut-off point of 12. ( e) Kaplan-Meier analysis for DFS of high-risk breast cancer patients (n = 204) treated with anthracycline-based chemotherapy ± endocrine therapy using the optimized PITX2 cut-off point of PMR equiv = 12 (HR 2.478; p < 0.001). Upper line: PMR ≤ 12. Lower line: PMR > 12. ( f) Kaplan-Meier analysis for DFS of high-risk breast cancer patients treated with anthracycline-based chemotherapy plus endocrine therapy (n = 96) using the optimized PITX2 cut-off point of PMR equiv = 12 (HR 3.057; p = 0.002). Upper line: PMR ≤ 12. Lower line: PMR > 12. Kaplan-Meier analysis: n = 2 patients with DFS at 147 and 166 months were censored for DFS analysis with follow-up time of 120 months.

Article Snippet: Those studies include a proprietary microarray platform developed by the company Epigenomics AG (Berlin, Germany) for on DNA methylation based biomarker screening using bisulfite converted DNA (bisDNA) specific probes for the methylated and unmethylated status of CpG residues , or a ‘research use only’ (RUO) real-time PCR assay covering three of the most relevant CpG residues for clinical response prediction in tamoxifen treated breast cancer patients .

Techniques: Microarray, Methylation

Journal: Scientific Reports

Article Title: Clinical performance of an analytically validated assay in comparison to microarray technology to assess PITX2 DNA-methylation in breast cancer

doi: 10.1038/s41598-018-34919-1

Figure Lengend Snippet: Establishment of the transformation curve. Correlation of the PMR calc (mathematically converted microarray data) and PMR exp (data determined by therascreen PITX2 RGQ PCR assay) with 121 samples (41 ER−; 80 ER+). Coefficient factors: r-squared = 0.5219; r = 0.722.

Article Snippet: Those studies include a proprietary microarray platform developed by the company Epigenomics AG (Berlin, Germany) for on DNA methylation based biomarker screening using bisulfite converted DNA (bisDNA) specific probes for the methylated and unmethylated status of CpG residues , or a ‘research use only’ (RUO) real-time PCR assay covering three of the most relevant CpG residues for clinical response prediction in tamoxifen treated breast cancer patients .

Techniques: Transformation Assay, Microarray